A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials
Public ClinicalTrials.gov record NCT01853254. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a (Pegasys®) as Monotherapy or in Combination With Ribavirin (Copegus®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This open-label, non-randomized, single arm study will provide treatment or re-treatment with Pegasys (peginterferon alfa-2a) as monotherapy or in combination with Copegus (ribavirin) to patients with chronic hepatitis C infection. Patients who have received prior Pegasys monotherapy or combination therapy or who were considered eligible for treatment with Pegasys in previous donor protocols will be eligible to participate in this study. Treatment will be on investigator's decision according to the approved label for up to 48 weeks, with a 24-week safety follow-up.
Study identification
- NCT ID
- NCT01853254
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 272 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2003 (Type not available)
- Primary completion
- Sep 2011 (Actual)
- Completion
- Sep 2011 (Actual)
- Last update posted
- Sep 4, 2013
2003 – 2011
United States locations
- U.S. sites
- 49
- U.S. states
- 24
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35295-0005 | — |
| Not listed | La Jolla | California | 92037-1030 | — |
| Not listed | Long Beach | California | 90822 | — |
| Not listed | San Diego | California | 92123 | — |
| Not listed | San Diego | California | 92154 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Gainesville | Florida | 32610-0214 | — |
| Not listed | Gainesville | Florida | 32610 | — |
| Not listed | Jacksonville | Florida | 32209 | — |
| Not listed | Miami | Florida | 33136-1051 | — |
| Not listed | Orlando | Florida | 32803 | — |
| Not listed | Orlando | Florida | 32809 | — |
| Not listed | Sarasota | Florida | 34243 | — |
| Not listed | Wellington | Florida | 33414 | — |
| Not listed | Atlanta | Georgia | 30308 | — |
| Not listed | Atlanta | Georgia | 30309 | — |
| Not listed | Marietta | Georgia | 30060 | — |
| Not listed | Honolulu | Hawaii | 96817 | — |
| Not listed | Boise | Idaho | 83702 | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | Iowa City | Iowa | 52242 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | Baltimore | Maryland | 21205 | — |
| Not listed | Framingham | Massachusetts | 01702 | — |
| Not listed | Worcester | Massachusetts | 01655 | — |
| Not listed | Plymouth | Minnesota | 55446 | — |
| Not listed | Newark | New Jersey | 07102 | — |
| Not listed | Vineland | New Jersey | 08360 | — |
| Not listed | Binghamton | New York | 13903 | — |
| Not listed | Manhasset | New York | 11030 | — |
| Not listed | New York | New York | 10016 | — |
| Not listed | New York | New York | 10021 | — |
| Not listed | Poughkeepsie | New York | 12601 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Statesville | North Carolina | 28677 | — |
| Not listed | Cleveland | Ohio | 44106 | — |
| Not listed | Portland | Oregon | 97201 | — |
| Not listed | Lancaster | Pennsylvania | 17604-3200 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Providence | Rhode Island | 02905 | — |
| Not listed | Germantown | Tennessee | 38138 | — |
| Not listed | Dallas | Texas | 75203 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | San Antonio | Texas | 78215 | — |
| Not listed | Charlottesville | Virginia | 22906-0013 | — |
| Not listed | Bellevue | Washington | 98004 | — |
| Not listed | Seattle | Washington | 98133 | — |
| Not listed | Tacoma | Washington | 98403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01853254, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2013 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01853254 live on ClinicalTrials.gov.